Clinical trials
Phase 3 Hemoglobinuria, Paroxysmal trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2004 | 3 |
| 2005 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
| Active, not recruiting | 6 |
| Recruiting | 6 |
| Not yet recruiting | 4 |
| Terminated | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alexion Pharmaceuticals, Inc. | 12 |
| Novartis Pharmaceuticals | 5 |
| Regeneron Pharmaceuticals | 5 |
| Hoffmann-La Roche | 3 |
| AKARI Therapeutics | 2 |
| AO GENERIUM | 2 |
| Apellis Pharmaceuticals, Inc. | 2 |
| Biocad | 2 |
| Chengdu Suncadia Medicine Co., Ltd. | 2 |
| Nanjing Chia-tai Tianqing Pharmaceutical | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemoglobinuria, Paroxysmal | 48 |
| Anemia | 5 |
| Hemolysis | 5 |
| Hemoglobinuria | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Leukemia, Myelomonocytic, Juvenile | 2 |
| Lymphoma, Non-Hodgkin | 2 |
| Myelodysplastic Syndromes | 2 |
| Anemia, Hemolytic | 1 |
| Bone Marrow Diseases | 1 |
Trials
Showing 76 to 48 of 48. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.